It looks like you are using an older version of Internet Explorer which is not supported. We advise that you update your browser to the latest version of Microsoft Edge, or consider using other browsers such as Chrome, Firefox or Safari.

Home > Dosing

JAKAVI is a twice-daily, oral treatment for patients with
steroid-refractory (SR) acute or chronic GvHD1

JAKAVI: the only approved option for SR GvHD patients

Starting dose for GvHD

Dosing modifications are available depending on your patient’s blood values1

Dosing modifications
*10 mg twice daily to 5 mg twice daily or 5 mg twice daily to 5 mg once daily.

See Full Summary of Product Characteristics for further details on dose modifications and use in special populations.

ANC, absolute neutrophil count; ULN, upper limit of normal.

JAKAVI is the only approved option for SR GvHD and offers adjustable dosing to fit patient needs1

Learn more about GvHD
Explore the efficacy of JAKAVI in GvHD
See safety results from the REACH trials
Reference
  1. JAKAVI® (ruxolitinib) tablets: EU Summary of Product Characteristics. Novartis; January 2022.

This is an international website for JAKAVI® (ruxolitinib) and is intended for healthcare professionals outside of the United States. If you are a U.S. resident, please click here or on the U.S. Residents link on this page.

© 2024 Novartis Pharma AG. All rights reserved.
117343-2 6/22
Use of this website is subject to our Terms of Use.